COMP <GO>
ANL vs ABUS // EV/EBITDA & P/E VALUATION
Adlai Nortye Group Ltd. (NASDAQ) VS. Arbutus Biopharma Corporation (NASDAQ) • 15-METRIC TALLY: ANL 1
— ABUS 1
■ METRIC PARITY
LAST: $10.28 (+0.78%) • MKT CAP: $662.0M
valuation
—
LAST: $4.28 (-0.93%) • MKT CAP: $656.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANL VS. ABUS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANL | ABUS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -6.04% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 128.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.34 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.6 | 39.9 | -8.32 | ABUS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $662.0M | $656.0M | $6.0M | ANL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANL REV | ABUS REV | ANL GROSS % | ABUS GROSS % | ANL FCF | ABUS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $14.1M | — | — | — | -$39.6M |
| FY 2024 | — | $6.2M | — | — | — | -$65.0M |
| FY 2023 | — | $18.1M | — | — | — | -$85.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANL // BETA —
ABUS // BETA —